0.8151
Cue Biopharma Inc stock is traded at $0.8151, with a volume of 172.77K.
It is up +2.46% in the last 24 hours and up +9.93% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.7955
Open:
$0.84
24h Volume:
172.77K
Relative Volume:
0.61
Market Cap:
$62.64M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.8957
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
+12.04%
1M Performance:
+9.93%
6M Performance:
+6.40%
1Y Performance:
-33.73%
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CUE
Cue Biopharma Inc
|
0.8151 | 61.13M | 9.53M | -44.61M | -38.32M | -0.91 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-13-24 | Initiated | Jefferies | Buy |
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Nov-21-22 | Initiated | Piper Sandler | Overweight |
Jan-13-22 | Initiated | H.C. Wainwright | Buy |
Jan-03-22 | Initiated | Craig Hallum | Buy |
Nov-24-20 | Initiated | Berenberg | Buy |
Apr-09-20 | Initiated | Stifel | Buy |
Jan-28-20 | Initiated | BTIG Research | Buy |
Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
What dividend safety score for Cue Biopharma Inc. stockRecession Risk & Long-Term Safe Investment Plans - newser.com
Is Cue Biopharma Inc. (1UC) stock undervalued after correctionTrade Signal Summary & Free Real-Time Market Sentiment Alerts - newser.com
What recovery options are there for Cue Biopharma Inc.Buy Signal & Momentum Based Trading Ideas - newser.com
Is Cue Biopharma Inc. stock a top momentum play2025 Technical Overview & Risk Controlled Swing Trade Alerts - newser.com
Published on: 2025-10-12 06:58:11 - newser.com
What drives Cue Biopharma Inc stock priceValue Stock Picks & Low Cost Trading Ideas - earlytimes.in
Will Cue Biopharma Inc. stock recover after recent dropJuly 2025 Momentum & Verified Momentum Watchlists - newser.com
Using portfolio simulators with Cue Biopharma Inc. includedLayoff News & Community Consensus Stock Picks - newser.com
How Cue Biopharma Inc. (1UC) stock stacks up against competitorsJuly 2025 Pullbacks & Weekly High Potential Stock Alerts - newser.com
Cue Biopharma stock adds to gains after Nobel Prize validates CUE-401 approach - Investing.com Nigeria
Is Cue Biopharma (NASDAQ:CUE) Using Debt In A Risky Way? - simplywall.st
Tick level data insight on Cue Biopharma Inc. volatility2025 Growth vs Value & Reliable Breakout Forecasts - newser.com
Is it time to cut losses on Cue Biopharma Inc.Trade Risk Assessment & Daily Chart Pattern Signals - newser.com
Cue Biopharma, Inc. (NASDAQ:CUE) Sees Significant Drop in Short Interest - MarketBeat
Will Cue Biopharma Inc. stock reach all time highs in 2025July 2025 Intraday Action & Safe Entry Point Alerts - newser.com
Reversal indicators forming on Cue Biopharma Inc. stockAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
Will breakout in Cue Biopharma Inc. lead to full recoveryVolume Spike & Daily Growth Stock Tips - newser.com
Developing predictive dashboards with Cue Biopharma Inc. dataMarket Sentiment Report & Free Growth Oriented Trading Recommendations - newser.com
Market reaction to Cue Biopharma Inc.’s recent news2025 Top Decliners & Daily Profit Focused Screening - newser.com
Cue Biopharma names Usman Azam as new CEO and president - The Pharma Letter
Building trade automation scripts for Cue Biopharma Inc.2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com
Cue Biopharma names Usman Azam as new CEO, shifts focus to autoimmune disease - Investing.com Nigeria
Cue Biopharma Appoints Usman “Oz” Azam, M.D., as CEO - citybiz
Cue Biopharma Appoints Usman Azam as New CEO - TipRanks
Cue Biopharma, Inc. Appoints Usman ?Oz? Azam, M.D. as President, Effective September 29, 2025 - MarketScreener
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):